VERU · Veru Inc. · Financials
$2.48
-0.10 (-3.88%)
At close · Sep 9
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt regarding our ability to continue as a going concern for a period of twelve months subsequent to the issuance date of the financial statements included in this report. Certain elements of our operating plan to alleviate the conditions that raise substantial doubt, including but not limited to our ability to secure equity financing or other financing alternatives, are outside of our control and cannot be included in management's evaluation under the requirements of ASC 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months subsequent to the issuance date of the financial statements included in this report.”View the 10-Q filed Aug 10, 2026
Market Cap
$45.01M
Shares
17.05M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$16.89M
+3.6%
FY2024
Net Income
-$22.73M
+39.9%
FY2025
Gross Margin
34.67%
-11.8pp
FY2024
Operating Margin
-214.19%
+361.3pp
FY2024
Diluted EPS
-$11.00
-4.8%
FY2023
Operating Cash Flow
-$30.04M
-38.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | $16.89M | $16.3M | $39.35M | $61.26M | $42.59M | $31.8M | $15.86M | $13.66M | $22.13M | $32.6M | $24.49M | $31.46M | $35.03M | $18.57K | $22.22M | $27.54M | |
| — | — | $11.03M | $8.73M | $8.76M | $13.33M | $11.81M | $10.15M | $7.09M | $6.64M | $8.78M | $13.63M | $11.37M | $13.95M | $14.41M | $8.7M | $9.3M | $14.03M | |
| — | — | $5.85M | $7.57M | $30.59M | $47.93M | $30.79M | $21.66M | $8.77M | $7.02M | $13.35M | $18.97M | $13.12M | $17.5M | $20.62M | $9.87M | $12.92M | $13.52M | |
| — | — | 34.67% | 46.43% | 77.73% | 78.24% | 72.28% | 68.1% | 55.3% | 51.4% | 60.33% | 58.18% | 53.58% | 55.65% | 58.86% | 53138.65% | 58.16% | 49.08% | |
| $11.76M | $15.59M | $12.78M | $51.2M | $70.91M | $32.69M | $16.94M | $13.74M | $10.85M | $3.08M | $99.39K | $219.82K | $5575 | $4745 | $5277 | $10.93K | $381 | $105.92K | |
| $16.05M | $19.94M | $24.61M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $28.22M | — | $31.18M | $48.06M | $43.18M | $20.67M | $14.5M | $14.35M | $14.81M | $11.5M | $8.66M | $12.13M | $9.13M | $7.49M | $9.63M | $6.54M | $6.57M | $7.01M | |
| — | — | — | $71K | $71K | $113K | $316K | $309.23K | $275.26K | $147.01K | — | — | — | — | — | — | — | — | |
| $113.15K | $152.11K | $268.18K | $269.87K | — | — | — | — | $176.79K | $334K | $422.87K | $494.26K | $589.34K | $556.3K | $461.45K | $464.91K | $466.54K | $268.38K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $1.93M | — | |
| $27.82M | $35.53M | $37.39M | $107.07M | $114.08M | $53.36M | $31.43M | $28.09M | $29.64M | $15.51M | $10.33M | $12.35M | $9.2M | $7.71M | $9.68M | $6.57M | $8.58M | $8.8M | |
| -$19.19M | -$24.75M | -$36.17M | -$93.78M | -$83.49M | $12.97M | -$14.75M | -$6.44M | -$20.87M | -$8.49M | $3.02M | $6.62M | $3.92M | $9.79M | $10.94M | $3.3M | $4.35M | $4.72M | |
| — | — | -214.19% | -575.46% | -212.14% | 21.18% | -34.62% | -20.24% | -131.57% | -62.2% | 13.64% | 20.3% | 16.02% | 31.12% | 31.23% | 17750.29% | 19.57% | 17.13% | |
| -$19.08M | -$24.6M | -$35.9M | -$93.51M | — | — | — | — | -$20.7M | -$8.16M | $3.44M | $7.11M | $4.51M | $10.35M | $11.4M | $3.76M | $4.82M | $4.99M | |
| — | — | $607.47K | $2.43M | $4.37M | $4.89M | $4.62M | $4.71M | $2.95M | — | — | — | — | — | — | — | — | — | |
| $5.08M | $9.07M | $909.12K | $1.11M | -$316.06K | -$8.71M | -$5.31M | -$5.89M | -$2.2M | -$108.38K | -$204.6K | $68.63K | $33.28K | $144.26K | -$147.91K | -$63.37K | — | — | |
| -$38.23M | — | — | -$92.67M | -$83.8M | $4.27M | -$20.05M | -$12.32M | -$23.07M | -$8.6M | $2.81M | $6.69M | $3.96M | $9.93M | $10.79M | $3.23M | $4.22M | — | |
| $0 | $0 | $0 | $480.21K | $236.4K | -$3.13M | -$1.08M | -$303.93K | $866.1K | -$1.99M | $2.47M | $2.34M | $1.52M | -$4.41M | -$4.51M | -$2.17M | -$2.51M | -$1.49M | |
| -$13.61M | -$22.73M | -$37.8M | -$93.15M | -$84.04M | $7.39M | -$18.97M | -$12.02M | -$23.94M | -$6.61M | $344.73K | $4.35M | $2.43M | $14.34M | $15.3M | $5.4M | $6.74M | $6.54M | |
| — | — | -223.86% | -571.6% | -213.55% | 12.07% | -44.55% | -37.79% | -150.89% | -48.42% | 1.56% | 13.33% | 9.93% | 45.59% | 43.67% | 29081.88% | 30.32% | 23.73% | |
| — | — | — | — | — | — | — | — | -$23.94M | -$8.6M | $344.73K | $4.35M | — | — | — | $5.4M | $6.74M | $6.46M | |
| — | — | — | — | — | — | — | — | — | — | $344.73K | $4.35M | $2.43M | $14.34M | $15.3M | $5.4M | $6.74M | $6.12M | |
| USD/shares | -$0.58 | -$1.55 | -$2.80 | -$11.00 | -$10.50 | $1.00 | -$2.80 | — | — | -$2.50 | $0.10 | $1.50 | $0.90 | $5.10 | $5.50 | $2.00 | $2.50 | $2.50 |
| USD/shares | -$3.50 | — | — | -$11.00 | -$10.50 | $0.90 | -$2.80 | — | — | -$2.50 | $0.10 | $1.50 | $0.80 | $5.00 | $5.30 | $1.90 | $2.40 | $2.40 |
| shares | — | 14.65M | 13.49M | 8.5M | 8.01M | 7.63M | 6.68M | 6.33M | 5.39M | 3.46M | 2.87M | 2.85M | 2.85M | 2.84M | 2.77M | 2.73M | 2.7M | 2.57M |
| shares | — | — | — | 8.5M | 8.01M | 8.38M | 6.68M | 6.33M | 5.39M | 3.46M | 2.89M | 2.89M | 2.89M | 2.87M | 2.89M | 2.9M | 2.85M | 2.78M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2015: $5.64M in buybacks, $31.51M in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.58×
EV/EBIT
—
P/E (TTM)
—
Peer median 3.75×
Peer medians compare against the 274 similar-size Biotechnology companies (of 537 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| FC2 Segment | $60,396,697 | $40,556,818 |
| Preboost Segment | $862,831 | $2,035,242 |
By Geography (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| United States | $5,354,090 | $8,370,202 | $31,430,235 | $48,938,821 | $30,338,115 |
| Other Geographical Areas | $4,696,800 | $5,985,078 | — | — | — |
| Brazil | $2,760,540 | — | — | — | — |
| Mozambique | $2,172,840 | — | — | — | — |
| South Africa | $1,902,149 | $1,941,678 | — | — | — |
| Other Countries | — | — | $7,924,117 | $12,320,707 | $12,253,945 |
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| FC2 Female Condom | $16,886,419 | $16,283,945 | — | — |
| Product And Service Other | $0 | $13,013 | — | — |
| FC2 Global Public Health Sector | — | — | $9,128,858 | $13,926,249 |
| FC2 U.S. Prescription Channel | — | — | $30,223,079 | $46,470,448 |
| Other Products | — | — | $2,415 | $862,831 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| Sexual Health Segment | $44,015,921,000 | $26,495,126,000 |
| Corporate | $2,346,851,000 | -$24,370,763,000 |
| Research and Development Segment | -$33,390,115,000 | -$16,871,057,000 |
Key facts
CIK
863894
CUSIP
92536C202
13F (30d)
41 filings
41 filers
Visit website
Investor relations